- Home
- USEA vs QNCX Comparison
USEA vs QNCX Comparison
Compare USEA & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | USEA | QNCX |
|---|---|---|
| Founded | 2004 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 20.2M | 19.9M |
| IPO Year | 2022 | 2019 |
Fundamental Metrics
Financial Performance| Metric | USEA | QNCX |
|---|---|---|
| Price | $2.34 | $1.25 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 37.0K | ★ 54.5M |
| Earning Date | 05-21-2026 | 04-10-2026 |
| Dividend Yield | ★ 11.22% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $5.55 | N/A |
| Revenue Next Year | $4.60 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.17 | $0.08 |
| 52 Week High | $2.31 | $4.55 |
Technical Indicators
Market Signals| Indicator | USEA | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 71.30 | 64.12 |
| Support Level | $1.63 | $1.17 |
| Resistance Level | N/A | $1.50 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | 0.02 | -0.03 |
| Stochastic Oscillator | 97.14 | 20.83 |
Price Performance
Historical ComparisonAbout USEA United Maritime Corporation
United Maritime Corp is an international shipping company currently specializing in world-wide seaborne transportation services. It currently operates a fleet of dry bulk vessels, comprising Panamax, Capesize and Kamsarmax vessels. Its vessels include Dukeship, Nisea, Cretansea, Chrisea, Synthesea, and Exelixsea.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. Its proprietary AIDE technology is an inventive drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells. Its Phase 3 asset, eDSP, leverages the AIDE technology to encapsulate DSP into a patient's own red blood cells, and is targeted to treat a rare pediatric neurodegenerative disease, A-T.